Full Press Release Details
NextCure Provides Business Update and
Reports Third Quarter 2024 Financial Results
BELTSVILLE, Md. - November 7, 2024 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported third-quarter 2024 financial results.
"The November SITC presentation of LNCB74 preclinical data will highlight the differentiation of our B7-H4 ADC from other ADC's that also target B7-H4. We plan to file an IND in the fourth quarter of this year and advance into Phase 1, shortly following receipt of an FDA safe-to-proceed letter," said Michael Richman, NextCure's president and CEO. "Additionally, while the NC410 combo has shown encouraging Phase 1b clinical activity in both ovarian cancer and CRC patients, we plan to conclude the current trial and seek a partner to advance the program, allowing us to focus our resources on advancing the development of LNCB74."
Business Highlights and Near-Term Milestones
NC410 (LAIR-2 fusion)
Preclinical Non-Oncology Programs Seeking a Partner or Third Party Financing
Financial Results for Quarter Ended September 30, 2024
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. www.nextcure.com
Forward-Looking Statements
Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "continue," "could," "should," "due," "estimate," "expect," "intend," "hope," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "target," "towards," "forward," "later," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.
Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure's limited operating history and not having any products approved for commercial sale; NextCure's history of significant losses; NextCure's need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; and NextCure's dependence on key personnel. More detailed information on these and additional factors that could affect NextCure's actual results are described under the heading "Risk Factors" in NextCure's most recent Annual Report on Form 10-K and in NextCure's other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
| Selected Financial Information | ||||||||||||
| Selected Statement of Operations Items: | Three Months Ended | Nine Months Ended | ||||||||||
| September 30, | September 30, | |||||||||||
| (in thousands, except share and per share amounts) | 2024 | 2023 | 2024 | 2023 | ||||||||
| Operating expenses: | ||||||||||||
| Research and development | $ | 8,770 | $ | 11,010 | $ | 32,586 | $ | 36,104 | ||||
| General and administrative | 3,725 | 4,608 | 12,165 | 15,743 | ||||||||
| Restructuring and asset impairment | - | - | 2,542 | - | ||||||||
| Loss from operations | (12,495) | (15,618) | (47,293) | (51,847) | ||||||||
| Other income, net | 955 | 1,317 | 3,242 | 3,591 | ||||||||
| Net loss | $ | (11,540) | $ | (14,301) | $ | (44,051) | $ | (48,256) | ||||
| Net loss per common share - basic and diluted | $ | (0.41) | $ | (0.51) | $ | (1.58) | $ | (1.73) | ||||
| Weighted-average shares outstanding - basic and diluted | 27,975,840 | 27,839,968 | 27,950,634 | 27,814,655 | ||||||||
| Selected Balance Sheet Items: | ||||||||||||
| September 30, | December 31, | |||||||||||
| (in thousands) | 2024 | 2023 | ||||||||||
| Cash, cash equivalents, and marketable securities | $ | 75,308 | $ | 108,299 | ||||||||
| Total assets | $ | 90,345 | $ | 128,038 | ||||||||
| Accounts payable and accrued liabilities | $ | 8,672 | $ | 6,883 | ||||||||
| Total stockholders' equity | $ | 75,592 | $ | 114,421 |
Timothy Mayer, Ph.D.
Chief Operating Officer